GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Largest first-time venture capital fund to close in 2020 focused on US/EU biotech

SR One Completes Spin-out from GSK and Closes First Fund at $500 Million

AstraZeneca

BioNTech SE

Johnson & Johnson

Moderna

Novavax

Pfizer

Sanofi

Dr. Angela Rasmussen explains why news from mRNA vaccine trials is so promising and shares tips for investors thinking about buying stocks like Pfizer and Moderna.

A Virologist Explains: mRNA Coronavirus Vaccines And What Investors Should Know

FDA grants breakthrough designation to Glaxo's (GSK) long-acting injectable cabotegravir to decrease the risk of HIV acquisition in at-risk populations.

Glaxo (GSK) Candidate Gets Breakthrough Tag for HIV Prevention

Bayer AG

With immobile stock prices and a hangover of legal issues, these CEOs might be glad Wall Street doesn't operate like a democracy.

Investors Wish They Could Vote These 2 Healthcare CEOs Out

BHP Billiton

ConocoPhillips

Chevron

Rio Tinto plc Sponsored

Total

Vale S.A.

Exxon Mobil

In this article we present the list of 10 Best Dividend Stocks To Buy According To Billionaire Ken Fisher. Click to skip ahead and see the  5 Best Dividend Stocks To Buy According To Billionaire Ken Fisher.

10 Best Dividend Stocks To Buy According To Billionaire Ken Fisher

Adaptive Biotechnologies

Adaptive Biotechnologies beat expectations for its fiscal third quarter as the Seattle company continues to use its immune medicine platform in the fight against COVID-19.

Adaptive Biotechnologies posts $26.3M in Q3 revenue, inks partnership with GlaxoSmithKline

AbbVie

GSK and ABBV are both attractively valued and high-yield picks available in the pharma space, discounted for their respective generics-eroded segments. We think that neither is a bad option in the long term, but would opt for GSK due to its lesser focus on oncology, a market that is becoming more and more crowded.

GlaxoSmithKline Or AbbVie: Choices In High-Yield Pharma

Bristol-Myers

Citigroup

Merck

Seaboard

Kahn Brothers (Trades, Portfolio) has released its third-quarter portfolio. Throughout the portfolio holdings were reduced or sold completely, with the largest changes coming from Merck & Co. Inc. (NYSE:MRK), Bristol-Myers Squibb Company (NYSE:BMY), GlaxoSmithKline PLC (NYSE:GSK), Citigroup Inc. (NYSE:C) and Seaboard Corp. (SEB).

Kahn Brothers' Biggest 3rd-Quarter Sells

ABB Ltd.

Iron Mountain

Kraft Heinz

Prudential Financial

AT&T

We selected 9 defensive Dividends Aristocrats from 9 Sectors with average dividend yield of 6.7%, including several yielding more than 9%. The stocks in our selection have relatively low correlation with each other and therefore bring an additional diversification benefit as a portfolio.

9 Dividend Aristocrats With Yield Up To 9%

The European Commission has joined the Food and Drug Administration in accepting Zejula as a front-line therapy.

EU Regulator Grants Label Expansion for GlaxoSmithKline's Ovarian Cancer Therapy

Glaxo (GSK) witnesses recovery in vaccinations rates in the third quarter. Performance of Pharmaceuticals and Consumer Healthcare businesses improve.

Glaxo (GSK) Q3 Earnings Top, Vaccines Segment on Recovery Path

GlaxoSmithKline PLC (GSK) CEO Emma Walmsley on Q3 2020 Results - Earnings Call Transcript

Sanofi and GlaxoSmithKline have committed 200 million doses of their experimental coronavirus vaccine to a global effort to distribute shots around the world, the drugmakers said Wednesday. The doses will go to the COVAX Facility, a World Health Organization-backed initiative meant to give rich and poor countries alike equal access to crucial COVID-19 vaccines once.

Sanofi, GlaxoSmithKline pledge 200M COVID-19 vaccines for global use

The companies hope to apply for approval in the first half of 2021.

GSK And Sanofi Pledge 200 Million Vaccine Doses To Covid-19 Alliance

Sanofi and GSK's vaccine is further behind in clinical development than some of the front-runners like Pfizer, Moderna and AstraZeneca, which are all in late-stage trials.

Sanofi, GSK to provide 200 million Covid vaccine doses to WHO global immunization program

Glaxo beats earnings estimates in the third quarter of 2020 but misses the same for revenues. Stock down.

Glaxo (GSK) Beats Earnings Estimates in Q3, Revenues Miss

Britain's GSK said on Wednesday it expects full-year adjusted earnings to be at the lower end of its forecast as the COVID-19 pandemic disrupts vaccination rates, especially for its blockbuster shingles vaccine.

GSK expects full-year earnings to be at lower end of its forecast

Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine

Let us take a look at four drug/biotech companies due to release their quarterly results on Oct 28.

Drug/Biotech Stock Q3 Earnings on Oct 28: GSK, AMGN & More

GlaxoSmithKline (GSK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why GlaxoSmithKline (GSK) Might Surprise This Earnings Season

Glaxo's (GSK) Pharmaceutical and Consumer Healthcare segments are likely to have driven third-quarter sales. Results will provide clarity on the impact of coronavirus on the company's vaccine business.

Is a Beat in Store for Glaxo (GSK) This Earnings Season?

Seagen

Vertex Pharmaceuticals

Let us take a look at some drug/biotech stocks including Glaxo (GSK) and Merck (MRK) that are poised to beat on earnings for the third quarter.

5 Big Pharma/Biotech Stocks Set to Trump Q3 Earnings Estimates

Alnylam Pharmaceuticals

Biogen

Vir Biotechnology

Two small biotechs collaborated to find a coronavirus vaccine, but one of them may come out way ahead due to its expertise and other partnerships.

Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?

Inovio Pharmaceuticals

The race to develop a safe and effective COVID-19 vaccine is well under way, setting the stage to bring to market the fastest vaccine in history.

There are seven coronavirus vaccine candidates being tested in the U.S. — here’s where they stand

CureVac B.V

There's little doubt that COVID-19 vaccines will save many lives, but that doesn't mean investors will be rewarded.

Is the Coronavirus Vaccine Market Oversaturated?

News for GlaxoSmithKline Stock (GSK)